The Vascutek Custom Fenestrated Anaconda Post-Market Surveillance Study

NCT ID: NCT01826344

Last Updated: 2015-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

628 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicentre, prospective, observational post-market registry (follow-up 1 month, 1 year, 2 years, 3 years, 4 years and 5 years) to monitor the post-market clinical safety and effectiveness of the Vascutek AnacondaTM Custom Fenestrated Stent Graft in patients with a short infrarenal neck of \<15mm or juxta-renal abdominal aortic aneurysms who, in the opinion of the treating physician, are anatomically suitable for the AnacondaTM Custom Fenestrated Stent Graft and for whom a customised medical device is required.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AnacondaTM Custom Fenestrated Devices (CFD) are designed for the endovascular repair of abdominal aortic aneurysms (AAA) for cases where the aneurysm extends superiorly very close to or involving the renal arteries, leaving insufficient neck length for infrarenal device sealing. The non-CE marked devices are custom designed based on CT scan data of the patient's aorta and regulated in accordance with the Medical Device Directive (93/42/EEC) and associated country specific regulations as applicable.

The proximal end of the AnacondaTM fenestrated body device is positioned suprarenally, where it seals and fixates in the vessel by means of rings comprised of multiple turns of fine nitinol wire, attached to the fabric with polyester sutures, creating a self-expanding stent which provides a conformable seal with the vessel wall and assists in anchoring of the device. Nitinol hooks provide secure fixation within the suprarenal aorta. The saddle shape of the rings allows the superior mesenteric artery (SMA) or celiac artery to be accommodated in the valley of the top ring saddle in some cases.

The objective of the registry is to provide long term (5 year) safety and effectiveness data of all patients who consent to their data to be used in the registry. This data aims to demonstrate that the Vascutek AnacondaTM Custom Fenestrated Stent Graft is safe and effective in patients with a short infrarenal neck of \<15mm or juxta-renal abdominal aortic aneurysms who, in the opinion of the treating physician, are anatomically suitable for the AnacondaTM Custom Fenestrated Stent Graft.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aortic Aneurysms (AAA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A patient with juxta renal abdominal aortic aneurysms (AAA) who, in the opinion of the treating physician, is anatomically suitable for the Anaconda Fenestrated Graft and for whom a customised medical device is required.

Exclusion Criteria

1. Ruptured or symptomatic aneurysm
2. Clinically significant concomitant medical disease or infection
3. Connective Tissue Disease (e.g. Marfan's Syndrome)
4. Known allergy to nitinol, polyester or contrast medium
5. Excessive tortuosity of access vessels (femoral or iliac arteries)
6. Landing zone of less than 10mm in the visceral segment of the aorta
7. Inability to comply to follow up protocol
8. Access vessels less than 6mm in diameter
9. Diseased or excessively tortuous access to target vessels
10. Target vessels of less than 5mm in calibre
11. Excessive calcification or thrombus at the intended landing zone which could affect sealing
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vascutek Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Franz Josef Spital

Vienna, , Austria

Site Status

Krankenhaus Hietzing

Vienna, , Austria

Site Status

Imelda Hospital

Bonheiden, , Belgium

Site Status

St Luc Brussels

Brussels, , Belgium

Site Status

University Hospital, Brussels

Brussels, , Belgium

Site Status

Grand Hôpital de Charleroi

Charleroi, , Belgium

Site Status

H.-Hartziekenhuis Roeselare-Menen

Roeselare, , Belgium

Site Status

Peter Lougheed Centre

Calgary, , Canada

Site Status

QE2 Hospital

Halifax, , Canada

Site Status

London Health Sciences Centre

London, Ontario, , Canada

Site Status

Royal Victoria Hospital

Montreal, , Canada

Site Status

The Ottawa Hospital

Ottawa, , Canada

Site Status

St Clare's Mercy Hospital

St. Johns, , Canada

Site Status

Toronto General Hospital

Toronto, , Canada

Site Status

Health Science Centre

Winnipeg, , Canada

Site Status

Hopital Pellegrin

Bordeaux, , France

Site Status

CHU Henri Mondor

Créteil, , France

Site Status

Chirurgien Vasculaire

Draguignan, , France

Site Status

Clinique Ambrose Paré

Nancy, , France

Site Status

La Pitie

Paris, , France

Site Status

Le Plessis Robinson

Paris, , France

Site Status

CHU Tours

Tours, , France

Site Status

Luisenhospital - Aachen

Aachen, , Germany

Site Status

University Hospital Aachen

Aachen, , Germany

Site Status

Klinikum Augsburg

Augsburg, , Germany

Site Status

Red Cross hospital clinic

Bremen, , Germany

Site Status

University of Cologne

Cologne, , Germany

Site Status

Klinikum Frankfurt Hochst

Frankfurt, , Germany

Site Status

Universitatsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

Krankenhaus Freital

Freital, , Germany

Site Status

Chirurgie am Waldweg

Göttingen, , Germany

Site Status

University of Groningen

Gröningen, , Germany

Site Status

Asklepios Klinik Altona

Hamburg, , Germany

Site Status

Medical Care Centre for Vascular Diseases

Hamm, , Germany

Site Status

Marienhospital

Kevelaer, , Germany

Site Status

Bonifacius Hospital

Lingen, , Germany

Site Status

University Hospital

Munich, , Germany

Site Status

DRK Krankenhaus Neustrelitz

Neustrelitz, , Germany

Site Status

Krankenhaus Barmherzige Bruder

Regensburg, , Germany

Site Status

University Hospital

Regensburg, , Germany

Site Status

Klinikum Solingen

Solingen, , Germany

Site Status

Marien-Hospital Witten

Witten, , Germany

Site Status

University of Bologna

Bologna, , Italy

Site Status

Ospedale San Francesco

Nuoro, , Italy

Site Status

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervel

Palermo, , Italy

Site Status

San Filippo Neri Hospital

Rome, , Italy

Site Status

Centre Cardio Thoracique

Monaco, , Monaco

Site Status

Jeroen Bosch Hospital

's-Hertogenbosch, , Netherlands

Site Status

Medisch Spectrum Twente

Enschede, , Netherlands

Site Status

Maastricht University Medical Centre

Maastricht, , Netherlands

Site Status

Erasmus University

Rotterdam, , Netherlands

Site Status

Isala Klinieken

Zwolle, , Netherlands

Site Status

Hospital Donostia

Donostia / San Sebastian, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital de Navarra

Pamplona, , Spain

Site Status

Hospital Universitari Parc Tauli

Sabadell, , Spain

Site Status

Uppsala University

Uppsala, , Sweden

Site Status

University Hospital Bern

Bern, , Switzerland

Site Status

Kantonsspital Graubunden

Chur, , Switzerland

Site Status

Royal Derby Hospital

Derby, , United Kingdom

Site Status

Frimley Park Hospital

Frimley, , United Kingdom

Site Status

Western Infirmary/Gartnavel

Glasgow, , United Kingdom

Site Status

Leeds General Infirmary

Leeds, , United Kingdom

Site Status

Leicester Royal Infirmary

Leicester, , United Kingdom

Site Status

Imperial (St Mary's / Charing X) Hospital

London, , United Kingdom

Site Status

Kings College Hospital

London, , United Kingdom

Site Status

The Royal Free Hospital

London, , United Kingdom

Site Status

The Royal London Hospital

London, , United Kingdom

Site Status

Freeman Hospital

Newcastle, , United Kingdom

Site Status

John Radcliffe Hospital

Oxford, , United Kingdom

Site Status

Royal Preston Hospital

Preston, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Canada France Germany Italy Monaco Netherlands Spain Sweden Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CFD001

Identifier Type: -

Identifier Source: org_study_id